A Service For Professionals Friday, October 20, 2017
Contact (202) 540-8337
Company News Today
A Service For Professionals Friday, October 20, 2017 11614 Sources 410,877,834 Articles 3,134,516 Readers
Contact (202) 540-8337

Emerald Health: An Exceptional Team with a Unique Spin -- CFN Media

/EINPresswire.com/ -- SEATTLE, WA--(Marketwired - Mar 27, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces an article discussing how Emerald Health Therapeutics Inc.'s (TSX VENTURE: EMH) exceptional management team and Board of Directors has taken a unique approach to the market by focusing on cannabinoid genetics.

Canada's cannabis industry could reach $22.6 billion over the coming years, according to Deloitte, with a retail market worth up to $8.7 billion. With only around 40 producers licensed by Health Canada thus far, there's a significant market opportunity for licensed producers to capitalize on this growth over time. Many licensed producers have already surpassed a half-billion dollar market capitalization, but there are also many smaller niche opportunities.

Assembling a World-Class Team
Emerald Health has built a world-class management team and Board of Directors that have carried out a combined $1+ billion in clinical trials and raise over $500 million in funding.

Executive Chairman Avtar Dhillon, MD, serves on the board of five public life science companies and led the turnaround of Inovio Pharmaceuticals Inc. from $10 million to a $1 billion company. CFO Sandra Pratt, CPA, CA, has also accumulated over 20 years of experience in accounting and finance with Angiotech Pharmaceuticals Inc., which grew into a company worth over $100 million.

President & CEO Bin Huang, PhD, MBA, has over 20 years of experience in life sciences including 15 years of serving as Chief Executive Officer. In terms of cannabis-specific experience, VP Production Traviss Graham has over 15 years of experience in cannabis production, processing, and product development, while VP R&D Frey Garabagi, PhD, has over 10 years of experience in plant molecular genetics and medical technologies.

Few producers in the space can lay claim to such a pharmaceutically qualified team, making Emerald better positioned than most to benefit from the opportunity in cannabinoid-based medicine.

Securing Government Funding
Emerald Health secured federal funding to characterize cannabis strains from the Canadian National Research Council's Industrial Research Assistance Program ("NRC-IRAP") in 2015.

The company was able to secure the funding with its rich collection of genetic materials, compelling research proposal, highly-credentialed team, and its proactive outreach to the NRC for support. In particular, the company proposed characterizing (or fingerprinting) mother plants, screening seeds to identify seeds with desirable cannabinoid/terpene profiles, and then developing those plants for individual patient needs.

Building upon this research, the company has developed a product line with a high level of genetic and product diversity. Core products include CBX (CBG, CBC, THCV, CBDV), CBD ( > 3% CBD), THC:CBD (THC=CBD), THC ( < 17% THC), and THC+ ( > 17% THC). These products enable different patients to access the right concentrations for their needs, such as a patient that's only looking for CBD without psychoactive THC.

The company also intends to conduct clinical trials of its own to demonstrate the utility of its broad product lines. With these study results in hand, the company will be able to effectively convince more doctors to prescribe the drug as a treatment for various indications. Proprietary cannabinoid drugs that have undergone clinical trials will also command a significant premium in the market and set the company apart from other licensed producers.

Please follow the link to read the full article:
http://www.cannabisfn.com/emerald-health-exceptional-team-unique-spin/

For more information, visit the company's website or CannabisFN's company profile.

About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Learn how to become a CFN Media featured company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

Contact:
Frank Lane
206.369.7050
flane@cannabisfn.com

Powered by EIN Presswire